Company Announcements

LYON, France--(BUSINESS WIRE)--Dec. 18, 2025-- Regulatory News:

Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced its financial calendar for 2026.

In addition to regular meetings with the financial community, investors can also find updated information on the company’s website (www.adocia.com).

All corporate information on the company such as its financial statements, its corporate presentation and its status is available on the company’s website, in the Investors’ section “Regulated Information”.

About Adocia

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.

The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) BioChaperone^® for the stabilization and enhancement of peptide formulations and combinations; 2) AdOral^®, an oral peptide delivery technology; 3) AdoShell^®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoXLong^TM, a long-acting peptide platform.

Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).

View source version on businesswire.com: https://www.businesswire.com/news/home/20251218443649/en/

Adocia
Olivier Soula
CEO
contactinvestisseurs@adocia.com
+33 (0)4 72 610 610
www.adocia.com

Ulysse Communication
Adocia Press & Investor Relations
Bruno Arabian
Nicolas Entz
adocia@ulysse-communication.com
+ 33 (0)6 87 88 47 26

Source: Adocia